Patients have been asking about peptides for years. The questions come up in almost every intake. A retired special operator with post-concussion symptoms heard about BPC-157 on a podcast. An executive whose father declined from vascular dementia wants to know about Cerebrolysin. A woman in early opioid recovery has seen DSIP mentioned in a forum. The answer from most physicians has been a version of the same thing: these molecules sit in a regulatory gray zone, licensed compounding pharmacies cannot make them, and if a patient wants to try one, they are sourcing from research-chemical vendors and flying blind.
That is starting to change.
The FDA has signaled a meaningful shift in how it treats compounded peptides. For the better part of three years, licensed pharmacies were blocked from producing a set of molecules that clinicians and patients were asking for, while demand moved offshore into a market the agency could not regulate. That prohibition is now unwinding. The path forward is procedural and slower than the headlines suggest, but the direction is unambiguous. Compounds that have been off-limits are moving back into the clinical conversation.
This matters more for brain medicine than for almost any other specialty. Most of the peptides in question are not cosmetic. Several act directly on the central nervous system, on mechanisms neurologists care about: neuroinflammation, synaptogenesis, sleep architecture, and cerebral perfusion. A short list makes the point.
BPC-157 is a fifteen-amino-acid peptide derived from gastric juice. In rodent models of traumatic brain injury it reduces cerebral edema and inflammation in the hippocampus. Cerebrolysin, used widely in Europe for acute ischemic stroke, has neurotrophic properties that no other pharmaceutical replicates. DSIP, delta sleep-inducing peptide, has been studied since the 1970s for its effects on opioid withdrawal and chronic insomnia. Dihexa is a small angiotensin IV analog that crosses the blood-brain barrier and promotes synaptic growth in preclinical work. None of these are fringe compounds. They are molecules with serious mechanistic rationale and, in some cases, decades of human data accumulated outside the United States.
The Ban Backfired
The 2023 prohibition did not reduce peptide use in American patients. It moved demand into a supply chain the FDA cannot inspect. The agency has intercepted imported peptides with purity levels under forty percent. Patients who believed they were injecting a clinical-grade product were often injecting filler, contamination, or a compound chemically unrelated to what the vial claimed. In a population that is already vulnerable (post-concussion patients, people with early neurodegeneration, individuals in addiction recovery) the downside of that arrangement has been real and measurable.
This is the core point that is easy to miss. A regulated supply chain for these molecules is a patient-safety win, regardless of how anyone feels about the specific peptides. When a physician can write a prescription that goes to a licensed pharmacy with a verified certificate of analysis, the patient knows what they are getting. When the only path is a website in a jurisdiction with no enforcement, the patient does not. The choice is not between peptides and no peptides. The choice is between supervised peptides and unsupervised peptides, and informed practitioners should want the former.
What This Means for Patients
Three things, if you are paying attention to this space.
First, the timeline is longer than the headlines suggest. A regulatory shift at the agency level does not flip a switch at the pharmacy. The process moves through advisory committee review, public comment, and formal rulemaking. Months from now, not next week, licensed pharmacies will begin offering specific peptides for specific indications. Patience is part of the deal.
Second, the molecules most relevant to brain medicine will come up for review in stages. Expect peptides with the clearest mechanistic rationale and the strongest existing data to be cleared first. Expect products with muddier evidence, or with abuse potential, to face more friction. Any physician or clinic advertising these compounds today, before the regulatory door has actually opened, is operating ahead of the rules and should be treated with skepticism.
Third, the right response to a murky market has never been to look away. It is to demand provenance. At The Neurogenesis Project, when peptides become part of a patient's Intensive Brain Health Program, the standard is the same one we apply to every other component of care. Pharmacy-grade material. Verified certificate of analysis. Clinical rationale tied to a measurable deficit on the workup. Longitudinal tracking of the outcome. For Rescue From Rehab patients, that discipline matters even more. The whole point of that program is that patients in recovery deserve the same rigor we apply to an executive optimizing cognition. Arguably, they deserve more of it.
The Neuroeconomy runs on intact, high-functioning brains. The tools that help us protect, repair, and optimize neural tissue are not a luxury category. They are the infrastructure of a society that is going to need more cognitive capacity than it has ever needed before. When regulators make room for another set of those tools, physicians should be ready to use them well. That means knowing what the evidence says, knowing what the evidence does not yet say, and staying close enough to the science that when the door opens, the practice knows how to walk through it.